BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283 [PMID: 23180949 DOI: 10.3748/wjg.v18.i43.6277]
URL: https://www.wjgnet.com/1007-9327/full/v18/i43/6277.htm
Number Citing Articles
1
Yuan-wang Qiu, Li-hua Huang, Wen-long Yang, Zhen Wang, Bo Zhang, Yi-guang Li, Ting-ting Su, Hong-yan Zhou, Wei Xu, Xue-dong Wang, Ya-ping Dai, Jian-he Gan. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patientsInternational Journal of Infectious Diseases 2016; 43: 43 doi: 10.1016/j.ijid.2015.10.019
2
KASL clinical practice guidelines: management of chronic hepatitis BClinical and Molecular Hepatology 2016; 22(1): 18 doi: 10.3350/cmh.2016.22.1.18
3
Chang Hyeong Lee. Oral Antiviral Therapy for Chronic Hepatitis B Virus Infection: Is Continuous Treatment Needed?Gastroenterology & Hepatology: Open Access 2014; 1(1) doi: 10.15406/ghoa.2014.01.00005
4
Keunhee Kang, Ji Hoon Kim. Is HBsAg Loss an Ideal End-point of Oral Antiviral Therapy in Chronic Hepatitis B Patients?The Korean Journal of Gastroenterology 2014; 63(5): 329 doi: 10.4166/kjg.2014.63.5.329
5
E. Ridruejo, S. Marciano, O. Galdame, M. V. Reggiardo, A. E. Muñoz, R. Adrover, D. Cocozzella, N. Fernandez, C. Estepo, M. Mendizábal, G. A. Romero, D. Levi, T. Schroder, S. Paz, H. Fainboim, O. G. Mandó, A. C. Gadano, M. O. Silva. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavirJournal of Viral Hepatitis 2014; 21(8): 590 doi: 10.1111/jvh.12200
6
Naruhiko Nagata, Tatehiro Kagawa, Shunji Hirose, Yoshitaka Arase, Kota Tsuruya, Kazuya Anzai, Koichi Shiraishi, Tetsuya Mine. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis BBMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0454-z
7
Elia Moreno-Cubero, Robert T Sánchez del Arco, Julia Peña-Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel, Juan Ramón Larrubia. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?World Journal of Gastroenterology 2018; 24(17): 1825-1838 doi: 10.3748/wjg.v24.i17.1825
8
Margarita Papatheodoridi, George Papatheodoridis. Can we stop nucleoside analogues before HB sAg loss? Journal of Viral Hepatitis 2019;  doi: 10.1111/jvh.13091
9
Cristina Pérez-Cameo, Mònica Pons, Rafael Esteban. New therapeutic perspectives in HBV: when to stop NAsLiver International 2014; 34: 146 doi: 10.1111/liv.12398
10
Renato Medas, Rodrigo Liberal, Guilherme Macedo. Discontinuation of antiviral therapy in chronic hepatitis B patientsWorld Journal of Clinical Cases 2021; 9(24): 6979-6986 doi: 10.12998/wjcc.v9.i24.6979
11
Ching-Chung Lin, Ming-Jong Bair, Chih-Jen Chen, Keng-Han Lee, Ming-Jen Chen, Chia-Yuan Liu, Chen-Wang Chang, Kuang-Chun Hu, Tai-Cherng Liou, Shee-Chan Lin, Horng-Yuan Wang, Cheng-Hsin Chu, Shou-Chuan Shih, Tsang-En Wang. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patientsThe Kaohsiung Journal of Medical Sciences 2016; 32(1): 10 doi: 10.1016/j.kjms.2015.11.005
12
Junfeng Lu, Jin’e Li, Yali Liu, Shan Ren, Zhenhuan Cao, Yi Jin, Lina Ma, Chengli Shen, Xinyue Chen, Joerg F. Schlaak. Study on Post-Treatment Relapse in HBeAg Positive CHB PatientsPLOS ONE 2015; 10(11): e0141072 doi: 10.1371/journal.pone.0141072
13
Chern Hao Chong, Seng Gee Lim. When can we stop nucleoside analogues in patients with chronic hepatitis B?Liver International 2017; 37: 52 doi: 10.1111/liv.13314
14
Da-biao Chen, You-ming Chen, Jing Liu, Dong-ying Xie, Cui-rong Lu, Zhan-lian Huang, Rui-hua Zhu, Zhi-liang Gao. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patientsJournal of Clinical Virology 2014; 59(1): 50 doi: 10.1016/j.jcv.2013.11.002
15
Christine I. Wooddell, Adam J. Gehring, Man-Fung Yuen, Bruce D. Given. RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure StrategiesViruses 2021; 13(4): 581 doi: 10.3390/v13040581
16
Chih-Chien Yao, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chi-Sin Changchien, Mei-Chin Hsu, Chien-Hung Chen. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversionJournal of Gastroenterology and Hepatology 2015; 30(5): 918 doi: 10.1111/jgh.12874
17
Baek Gyu Jun, Sae Hwan Lee, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim, Soung Won Jeong, Jae Young Jang, Young Don Kim, Gab Jin Cheon. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis BThe Korean Journal of Gastroenterology 2016; 67(1): 28 doi: 10.4166/kjg.2016.67.1.28
18
Florian van Bömmel, Thomas Berg. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis BLiver International 2018; 38: 90 doi: 10.1111/liv.13654
19
Thomas Berg, Karl-Georg Simon, Stefan Mauss, Eckart Schott, Renate Heyne, Dietmar M. Klass, Christoph Eisenbach, Tania Mara Welzel, Reinhart Zachoval, Gisela Felten, Julian Schulze-zur-Wiesch, Markus Cornberg, Marjoleine L. Op den Brouw, Belinda Jump, Hans Reiser, Lothar Gallo, Tobias Warger, Jörg Petersen. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE studyJournal of Hepatology 2017; 67(5): 918 doi: 10.1016/j.jhep.2017.07.012
20
Florian Bömmel, Thomas Berg. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis BHepatology Communications 2021; 5(10): 1632 doi: 10.1002/hep4.1708
21
Tse-Ling Fong, Andy Tien, Kahee J. Jo, Danny Chu, Eddie Cheung, Edward A. Mena, Quang-Quoc Phan, Andy S. Yu, Wafa Mohammed, Andrew Velasco, Vinh-Huy LeDuc, Nickolas Nguyen, Steven-Bui Han, Mimi Chang, Ho S. Bae, Yong-Won Cho, Myron J. Tong, Stewart L. Cooper. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or TenofovirDigestive Diseases and Sciences 2015; 60(11): 3465 doi: 10.1007/s10620-015-3775-9
22
Wen-xiong Xu, Qian Zhang, Xiang Zhu, Chao-shuang Lin, You-ming Chen, Hong Deng, Yong-yu Mei, Zhi-xin Zhao, Dong-ying Xie, Zhi-liang Gao, Chan Xie, Liang Peng. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with RelapseCanadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/1817680
23
Apichat Kaewdech, Pimsiri Sripongpun. Challenges in the discontinuation of chronic hepatitis B antiviral agentsWorld Journal of Hepatology 2021; 13(9): 1042-1057 doi: 10.4254/wjh.v13.i9.1042
24
Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Henry L.Y. Chan, Maria Buti, Marc G. Ghany, Anuj Gaggar, Jenny C. Yang, George Wu, John F. Flaherty, G. Mani Subramanian, Stephen Locarnini, Patrick Marcellin. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis BHepatology Communications 2020; 4(1): 8 doi: 10.1002/hep4.1436
25
Chia-Chi Wang, Kuo-Chih Tseng, Tsai-Yuan Hsieh, Tai-Chung Tseng, Hans Hsienhong Lin, Jia-Horng Kao. Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAgAmerican Journal of Gastroenterology 2016; 111(9): 1286 doi: 10.1038/ajg.2016.109
26
George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi, Jörg Petersen. Discontinuation of oral antivirals in chronic hepatitis B: A systematic reviewHepatology 2016; 63(5): 1481 doi: 10.1002/hep.28438
27
Robério Amorim de Almeida Pondé. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approachMolecular Biology Reports 2021; 48(1): 843 doi: 10.1007/s11033-020-06056-4